Avoiding central nervous system bleeding during antithrombotic therapy: Recent data and ideas

Stroke

Volumn 36, Issue 7, 2005, Pages 1588-1593

  Hart, Robert G ^a   Tonarelli, Silvina B ^a   Pearce, Lesly A ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Minot ^*  (United States)

Author keywords

Anticoagulants; Antiplatelet; Antithrombotic therapy; Aspirin; Clopidogrel; Intracerebral hemorrhage; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; WARFARIN;

ADULT; AGE; AGED; ANTICOAGULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; FATALITY; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INCIDENCE; LONG TERM CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; UNITED STATES;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; BLOOD PRESSURE; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CLINICAL TRIALS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TICLOPIDINE; WARFARIN;

EID: 22044452252     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000170642.39876.f2     Document Type: Review

References (66)

1. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med. 1999;131:492-501.
2. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS. Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG, for the Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352: 1305-1316.
3. He I, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke. A meta-analysis of randomized controlled trials. JAMA. 1998;280: 1930-1935.
4. Collaborative overview of randomized trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
5. Hart RG, Halperin JL, McBride R, Benavente O, Man-Son-Hing M, Kronmal RA. Aspirin for the primary prevention of stroke and other major vascular events. Arch Neurol. 2000;57:326-332.
6. Ridker PM, Cook NR, Lee I-M, Gordon D, Gaziano JM, Manson JE, Hermekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
7. Thrift AG, McNeil JJ, Forbes A, Donnan GA. Risk of primary intracerebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: case-control study. BMJ. 1999;318:759-764.
8. Woo D, Sauerbeck LR, Kissela BM, Khoury JC, Szaflarski JP, Gebel J. Shukla R, Pancioli AM, Jauch EC, Menon AG, Deka R, Carrozzella JA, Moomaw CJ, Fontaine RN, Broderick JP. Genetic and environmental risk factors for intracerebral hemorrhage. Stroke. 2002;33:1190-1196.
9. Nilsson OG, Lindgren A, Stahl N, Brandt L, Saveland H. Incidence of intracerebral and subarachoid hemorrhage in southern Sweden. J Neurol Neurosurg Psych. 2000;69:601-607.
10. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164:880-884.
11. Saloheimo P, Juvela S, Hillbom M. Use of aspirin, epistaxis, and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people. Stroke. 2001;32:399-404.
12. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995;26:1471-1477.
13. Torn M, Algra A, Rosendaal FR. Oral anticoagulation for cerebral ischemia of arterial origin. High initial bleeding risk. Neurology. 2001;57: 1993-1999.
14. Torn M, van der Meer FJM, Rosendaal FR. Lowering the intensity of oral anticoagulant therapy. Effects on the risk of hemorrhage and thromboembolism. Arch Intern Med. 2004;164:668-673.
15. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003;139:893-900.
16. Pengo V, Legnani C, Noventa F, Palaretti G on behalf of the ISCOAT Study Group. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. Thromb Haemost 2001;85: 418-422.
17. Go AS, Hylek EM, Chang Y, Phillips KA, Renault LE, Capra AM, Jensvold NG, Selby JV, Singer DE. Anticoagulation therapy for stroke prevention in atrial fibrillation. How well do randomized trials translate into clinical practice? JAMA. 2003;290:2685-2692.
18. Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004;35:2362-2367.
19. Van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288:2441-2448.
20. Olsson SB, Executive Steering Committee on behalf of the SPORTIF ITI Investigators. Stroke prevention with the oral direct thrombin inhibitor ximegalatran compared with warfarin in patients with non-valvular atrial fibrillation: randomized controlled trial Lancet. 2003;362:1691-1698.
21. Sherman DG, Kim SG, Boop BS, Corley SD, DiMarco JP, Hart RG, Haywood LJ, Hoyte K, Kaufman ES, Kim MH, Nasco E, Waldo AL and the NHLBI AFFIRM Investigators. The occurrence and characteristics of stroke events in the AFFIRM Study. Arch Intern Med. 2005;165: 1185-1191.
22. Johnson CE, Lim WK, Workman BS. People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up. J Am Geriatric Soc. 2005;53: 655-659.
23. Buresly K, Eisenberg MJ, Zhang X, Pilote L. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med. 2005;165:784-789.
24. Wintzen AR, De Jonge H, Loeliger EA, Botts GTAM. The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol. 1984;16:533-538.
25. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, Singer DE. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141:745-752.
26. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019-1026.
27. Berwaerts J, Webster J. Analysis of risk factors involved in oral-anticoagulant-related intracranial hemorrhages. Q J Med. 2000;93: 513-521.
28. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in atrial fibrillation. Arch Intern Med 1996;156: 409-416.
29. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia. Patterns and risk factors. Neurology. 1999;53:1319-1327.
30. Hart RG, Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis. 1999;9:215-217.
31. Rosand J, Hylek EM, O'Donnel KC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathological study. Neurology. 2000;55:947-951.
32. Smith EE, Rosand J, Knudsen KA, Hylek EM, Greenberg SM. Leukoariosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology. 2002;59:193-197.
33. Wong KS, Chan YL, Liu JY, Gao S, Lam WWM. Asymptomatic microbleeds as a risk factor for aspirin-associated intracerebral hemorrhages. Neurology. 2003;60:511-513.
34. Fan YH, Zhang L, Lam WWM, Mok VCT, Wong KS. Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke. Stroke. 2003;34:2459-2462.
35. Oden A, Falen M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ. 2002;325:1073-1075.
36. Franke CL, DeJonge J, van Swieten JC, Op de Coul AAW, van Gijn J. Intracerebral hematomas during anticoagulant treatment. Stroke. 1990; 21:726-730.
37. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for the prevention of thromboembolism in atrial fibrillation: results of the Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-691.
38. Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997;42:857-865.
39. European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) Study Group. Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage. Stroke. 2003;34:e45-e47.
40. Sandercock P, Mielke O, Liu M, Counsell C. Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack. Cochrane Database of Systematic Reviews. 2005, Issue 2 (CD000248).
41. Kato H, Izumiyama M, Izumiyama K, Takahashi A, Itoyama Y. Silent cerebral microbleeds on T2*-weighted MRI. Correlation with stroke subtype, stroke recurrence, and leukoaraiosis. Stroke. 2002;33: 1536-1540.
42. Turpie AGG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh J. A comparison of aspirin with placebo in patients treated with warfarin and heart valve replacement. N Engl J Med. 1993; 329:524-529.
43. Medical Research Council's General Practice Research Framework. Thrombosis Prevention Trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet 1998; 351:233-241.
44. Chesebro JH, Fuster V, Elveback LR, McGoon DC, Pluth JR, Puga FJ, Wallace RB, Danielson GK, Orszulak TA, Piehler JM, Schaff HV. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin combined with dipyridamole. Am J Cardiol. 1983;51:1537-1541.
45. Altman R, Boulton F, Rouvier J, Raca R, de la Fuente R, Favaloro K. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg 1976;72:127-129.
46. Dale J, Myhre E, Loew D. Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. Am Heart J. 1980;99:746-751.
47. Huynh T, Theroux P, Bogaty P, Nasmith J, Solymoss S. Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation. 2001;103:3069-3074.
48. Lechat P, Lardoux H, Mallet A, Sanchez P, Derumeaux G, Lecompte T, Maillard L, Mas JL, Mentre F, Pousset F, Lacomblez L, Pisica G, Solbes-Latourette S, Raynaud P, Chaumet-Riffaud P. Anticoagulant (flunidone)-aspirin combination in patients with high risk atrial fibrillation. A randomized trial (Fluindone, Fibrillation Auriculaire, Aspirin et Contrast Spontane, FFAACS). Cerebrovasc Dis. 2001;12:245-252.
49. Laffort P, Roudaut R, Roques X, Lafitte S, Deville C, Bonnet J, Baudet E. Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St. Jude medical prosthesis: a clinical and transesophageal echocardiographic study. J Am Coll Cardiol. 2000;35: 739-746.
50. Gullov AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, Boysen G. Mini-dose warfarin and aspirin in atrial fibrillation. Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study (AFASAK 2). Arch Int Med. 1998;158:1513-1521.
51. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996;348:633-638.
52. Perez-Gomez F, Alegria E, Berjon J, Iriarte JA, Zumalde J, Salvador A, Mataix L. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular atrial fibrillation and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol. 2004; 44:1557-1566.
53. Meschengieser SS, Fondevilla CG, Frontroth J, Santarelli MT, Lazzari MA. Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc Surg. 1997;113:910-916.
54. Van Es RF, Jonker JCJ, Verheugt FWA, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study). Lancet. 2002;360:109-113.
55. Hurlen M, Abdelnoor M, Smith P, Erikseen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347: 969-974.
56. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative Studies Program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction. Circulation. 2002;105:557-563.
57. Diener H-C, Bogousslavsky J, Brass LM, Cimminello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet. 2004;364:331-337.
58. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
59. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without St-segment elevation. N Engl J Med 2001; 345:494-502.
60. Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Harris Y, Kittner S, Leurgans S. Aspirin and tidopidine for prevention of recurrent stroke in black patients. A randomized trial. JAMA. 2003;289:2947-2957.
61. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762.
62. Steinhubl SR, Berger PB, Mann JT, Fry ETA, DeLago A, Wilmer C, Topol EJ for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA. 2002;288:2411-2420.
63. Diener H-C, Lowenthal A. Antiplatelet therapy to prevent stroke: risk of brain hemorrhage and efficacy in atrial fibrillation. J Neurol Sci. 1997; 153:112.
64. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet. 2001; 358:1033-1041.
65. Chapman N, Huxley R, Anderson C, Bousser MG, Chalmers J, Colman S, Davis S, Donnan G, MacMahon S, Neal B, Warlow C, Woodward M. Effects of a peindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history. The PROGRESS Trial. Stroke. 2004;35:116-121.
66. Perry H, Davis B, Price T, Applegate WB, Fields WS, Guralnik JM, Kuller L, Pressel S, Stamler J, Probstfield JL. Effects of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA. 2000;284:465-471.